Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

SELECT TRIAL: Semaglutide, Central Fat, and Cardioprotection 🧪🏹🛡️

6:44
 
Share
 

Manage episode 515401786 series 2740117
Content provided by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

🫀📉 Published in The Lancet (Oct 22, 2025): SELECT trial investigators report that semaglutide reduced MACE by 20% in patients with obesity but without diabetes—independent of weight loss. Waist circumference, not weight, tracked with outcomes, yet explained only 33% of the benefit. This landmark analysis redefines GLP-1RAs as disease-modifying agents, not just weight-loss drugs.

👉 Read here: https://doi.org/10.1016/S0140-6736(25)01375-3

#SELECTTrial #Semaglutide #Cardiovascular #Obesity #GLP1RA #TheLancet

  continue reading

757 episodes

Artwork
iconShare
 
Manage episode 515401786 series 2740117
Content provided by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by MasterMedFacts LLC, Dr RR Baliga, MD, and MBA or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

🫀📉 Published in The Lancet (Oct 22, 2025): SELECT trial investigators report that semaglutide reduced MACE by 20% in patients with obesity but without diabetes—independent of weight loss. Waist circumference, not weight, tracked with outcomes, yet explained only 33% of the benefit. This landmark analysis redefines GLP-1RAs as disease-modifying agents, not just weight-loss drugs.

👉 Read here: https://doi.org/10.1016/S0140-6736(25)01375-3

#SELECTTrial #Semaglutide #Cardiovascular #Obesity #GLP1RA #TheLancet

  continue reading

757 episodes

Усі епізоди

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play